In January 2007, Actelion announced the successful completion of its cash tender offer for shares of CoTherix, Inc., thereby strengthening its PAH franchise by adding Ventavis(R) to its product offerings in the United States. Bayer Schering Pharma - the inventor of Ventavis(R) - markets the drug as the first inhaled prostacyclin in Europe and other countries outside the US.
More information is available at www.4ventavis.com.
About Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy. Approximately 100,000 people in Europe and the United States are afflicted with either primary or secondary forms of the disease related to conditions or tissue disorders that affect the lungs, such as scleroderma, lupus, HIV/AIDS or congenital heart disease.
PAH is associated with structural changes in both the pulmonary vasculature and the right ventricle. Recent advances (1) in the understanding of the pathogenic factors leading to the pulmonary vascular disease have led to the development of new therapies targeting specific pathways (the prostacyclin pathway; the endothelin pathway; and the nitric oxide pathway) (2).
|SOURCE Actelion Pharmaceuticals US, Inc.|
Copyright©2009 PR Newswire.
All rights reserved